Moreover, using an in vivo zebrafish xenograft of human melanoma we show reduced metastatic potential of MEKi‐resistant melanoma cells in response to combined treatment with trametinib and a novel Vps34 inhibitor PIK‐III,27 while, importantly, having no adverse effect on the development and survival of the zebrafish. This evidence concerns the gene PIK3C3 and melanoma.